Long COVID, C diff, Candida auris: This Week's Infectious Disease Stories to Watch

Article

Stay informed about the long-term effects of COVID-19, prevention strategies for recurrent C diff, and the emerging threat of drug-resistant Candida auris.

Recent Videos
Related Content
MAD-ID 2025 Highlights Fidaxomicin’s Role in Reducing C difficile Recurrence

MAD-ID 2025 Highlights Fidaxomicin’s Role in Reducing C difficile Recurrence

Sophia Abene
June 10th 2025
Article
C difficile, Antimicrobials, and the Patients Most Affected

C difficile, Antimicrobials, and the Patients Most Affected

Nina Cosdon
November 23rd 2022
Podcast
Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort

Investigational Oral Biologic Achieves 100% C difficile Clinical Cure in Preliminary Cohort

John Parkinson
April 3rd 2025
Article
New Meta-Analysis Highlights Most Effective Treatments for Clostridioides difficile Infection

New Meta-Analysis Highlights Most Effective Treatments for Clostridioides difficile Infection

Sophia Abene
February 6th 2025
Article
Investigational Live Biotherapeutic Product Significantly Reduces Risk of Recurrent Clostridioides difficile

Investigational Live Biotherapeutic Product Significantly Reduces Risk of Recurrent Clostridioides difficile

Contagion Editorial Team
January 24th 2025
Article
LPOXY Therapeutics Acquires Assets to Advance C difficile Protection for Antibiotic Patients

LPOXY Therapeutics Acquires Assets to Advance C difficile Protection for Antibiotic Patients

Sophia Abene
January 8th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.